Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 8/20 | 0.41 |
| ▸ | PYGL | P06737 | 3/20 | 0.41 |
| ▸ | PYGM | P11217 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12830828 | 0.94 | MEN1 (0.38) | PYGBPYGLPYGMMEN1KMT2A | |
| SCHEMBL21914139 | 0.94 | MEN1 (0.38) | PYGBPYGLPYGMMEN1KMT2A | |
| SCHEMBL13276873 | 0.89 | PYGB (0.39) | PYGBPYGLPYGMMEN1KMT2A | |
| SCHEMBL23722750 | 0.85 | PYGB (0.40) | PYGBPYGLPYGMMEN1KMT2A | |
| SCHEMBL9504070 | 0.85 | PYGB (0.40) | PYGBPYGLPYGMMEN1KMT2A | |
| SCHEMBL28413571 | 0.85 | PYGB (0.39) | PYGBPYGLPYGMMEN1KMT2A | |
| SCHEMBL23722745 | 0.85 | PYGB (0.39) | PYGBPYGLPYGMMEN1KMT2A | |
| SCHEMBL18393116 | 0.85 | PYGB (0.39) | PYGBPYGLPYGMMEN1KMT2A | |
| SCHEMBL30711127 | 0.85 | PYGB (0.39) | PYGBPYGLPYGMMEN1KMT2A | |
| SCHEMBL7157539 | 0.83 | MEN1 (0.54) | PYGBPYGLPYGMMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9023813-B2 | Synthesis and use of glycoside derivatives of propofol | NuTek Pharma Ltd. (US) | 2015-05-05 | — | — | US | disclosed |
| CN-103781472-A | Synthesis and use of propofol glycoside derivatives | NUTEK PHARMA LTD | 2014-05-07 | — | — | CN | disclosed |
| CN-103702670-A | Synthesis and use of glycoside pro-drug analogs | NUTEK PHARMA LTD | 2014-04-02 | — | — | CN | disclosed |
| US-20120295866-A1 | Synthesis And Use Of Glycoside Pro-Drug Analogs | NuTek Pharma Ltd. | 2012-11-22 | — | — | US | disclosed |
| US-20120264702-A1 | Synthesis And Use Of Glycoside Derivatives of Propofol | NuTek Pharma Ltd. | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295866-A1 | Synthesis And Use Of Glycoside Pro-Drug Analogs | GCG, CYP3A5, UGT1A6 | PYGB 132/4885PYGL 68/4885PYGM 168/4885 |
| US-20120264702-A1 | Synthesis And Use Of Glycoside Derivatives of Propofol | CYP3A5, CYP3A4, UGT1A4 | PYGB 173/4885PYGL 144/4885PYGM 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.